Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

4.980 -0.080 (-1.58%)
Streaming Delayed Price Updated: 9:47 AM EDT, Apr 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Altimmune's ALT-801 Achieves 5.4% Weight Loss Surpassing Pre-Established Target Of 2%
Altimmune Inc (NASDAQ: ALT) announced results from a prespecified 6-week interim analysis of its Phase 1 trial of ALT-801 in healthy, overweight, and obese volunteers. The study... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 347.96% to $9.9 during Wednesday's regular session. As of 12:30 EST, Aethlon Medical's stock is... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2021
Upgrades According to Barrington Research, the prior rating for Landec Corp (NASDAQ:LNDC) was changed from Market Perform to Outperform. Landec earned $0.09 in the third... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Mixed Ahead of ADP Report, Fed Minutes
Pre-open movers U.S. stock futures traded mixed in early pre-market trade after the Wall Street closed mixed in the previous session. Investors are awaiting earnings results from... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Altimmune's Intranasal COVID-19 Vaccine Candidate Neutralizes South African Variant, Animal Study Shows
Altimmune Inc (NASDAQ: ALT) has announced new results from a preclinical study of AdCOVID, the company's vaccine candidate. Data demonstrated that the vaccine... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA,... 
Via Benzinga
Exposures Product Safety
Looking Into Altimmune's Return On Capital Employed
During Q1, Altimmune's (NASDAQ:ALT) reported sales totaled $837.52 thousand. Despite a 38.25% in earnings, the company posted a loss of $14.86 million. Altimmune collected $2.31... 
Via Benzinga
ALTIMMUNE INC (ALT) Q1 2021 Earnings Call Transcript
ALT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For May 17, 2021
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:... 
Via Benzinga
Altimmune Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
On Tuesday, Altimmune stock received a positive adjustment to its Relative Strength Rating, from 78 to 86. The biopharma stock is worth watching. 
Via Investor's Business Daily
Altimmune's Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity After Single Dose
Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-... 
Via Benzinga
Exposures COVID-19
Could AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects?
The short answer: It depends. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.